Summary The Hippo pathway plays a crucial role in organ size control and tumor suppression, but its precise regulation has not been fully understood. In this study, we discovered phosphatidic acid (PA)-related lipid signaling as a key regulator of the Hippo pathway. Supplementing PA in various Hippo-activating conditions activates YAP. This PA-related lipid signaling is involved in the Rho-mediated YAP activation. Mechanistically, PA directly interacts with Hippo components LATS and NF2 to respectively disrupt the LATS-MOB1 complex formation and NF2-mediated LATS membrane translocation and activation. Inhibition of phospholipase D (PLD)-dependent PA production suppresses YAP oncogenic activities. PLD1 is highly expressed in breast cancer and positively correlates with YAP activation, suggesting their pathological relevance in breast cancer development. Taken together, our study not only reveals a role of PLD-PA lipid signaling in regulation of the Hippo pathway, but also indicates the PLD-PA-YAP axis as a potential therapeutic target for cancer treatment.

Tankyrase 1 (TNKS) and tankyrase 2 (TNKS2) belong to the poly(ADP-ribose) polymerase family of proteins, which use nicotinamide adenine dinucleotide to modify substrate proteins with ADP-ribose modifications. Emerging evidence has revealed the pathological relevance of TNKS and TNKS2, and identified these two enzymes as potential drug targets. However, the cellular functions and regulatory mechanisms of TNKS/2 are still largely unknown. Through a proteomic analysis, we defined the protein-protein interaction network for human TNKS/2 and revealed more than 100 high-confidence interacting proteins with numerous biological functions in this network. Finally, through functional validation, we uncovered a role for TNKS/2 in peroxisome homeostasis and determined that this function is independent of TNKS enzyme activities. Our proteomic study of the TNKS/2 protein interaction network provides a rich resource for further exploration of tankyrase functions in numerous cellular processes.

No abstract

In the gout population, the incidence of DM was lower in benzbromarone users than in benzbromarone non-users.

No abstract